SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Icebrg who wrote (2006)1/6/2004 12:17:16 PM
From: Ian@SI  Read Replies (2) of 3044
 
Time for me to eat some crow. Feuerstein was right.

Millennium Responds to Media Reports Related to Closure Of Phase II VELCADE Colorectal Trial

prnews

CAMBRIDGE, Mass., Jan. 6 /PRNewswire-FirstCall/-- Millennium
Pharmaceuticals, Inc. (Nasdaq: MLNM) today clarified that based on the completion of a pre-specified interim analysis, the Company has decided to stop further accrual to its phase II trial examining the utility of VELCADE(TM) (bortezomib) for Injection either alone or in combination with Camptosar(R) (irinotecan hydrochloride injection) in patients with metastatic colorectal cancer previously refractory to Camptostar. This decision was based on interim findings from both arms of the study that produced results that do not meet the pre-specified efficacy criteria for continuation of study
accrual. An update on the complete findings of this analysis will be provided at a medical meeting in 2004.

Although accrual has been closed, patients currently in the study experiencing clinical benefit may continue to receive treatment. Additional NCI and investigator-sponsored studies examining the utility of VELCADE in combination with other agents for the treatment of patients with non-refractory colorectal cancer are ongoing or planned.

The Company continues to investigate the full potential of VELCADE in both hematologic and solid tumors and currently has over 50 ongoing or planned clinical trials.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News